Q3 2025 GeneDx Holdings Corp Earnings Call Transcript
Key Points
- GeneDx Holdings Corp (WGS) reported a 52% year-over-year increase in third-quarter revenues, reaching $116.7 million.
- The company raised its 2025 revenue guidance to between $425 million and $428 million, reflecting strong business momentum.
- FDA granted breakthrough device designations to GeneDx's ExomeDx and GenomeDx tests, validating their industry-leading technology.
- GeneDx is expanding its sales force and commercial efforts, particularly targeting pediatricians, to drive future growth.
- The company achieved an adjusted gross margin of 74%, driven by improved reimbursement and lower costs of goods sold (COGS).
- Despite strong growth, GeneDx faces challenges with a high denial rate, impacting reimbursement rates.
- The company anticipates potential short-term impacts on average reimbursement rates as it expands into new markets.
- GeneDx is making significant investments in sales and marketing, which may temporarily affect operating margins.
- The transition to broader adoption of genomic testing in general pediatrics is expected to take 18 to 24 months, requiring substantial educational efforts.
- The company discontinued its hereditary cancer offerings, which will result in a near-zero revenue contribution from this segment in the fourth quarter.
Good day, and thank you for standing by. Welcome to the GeneDx third-quarter 2025 earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to turn the conference over to Sabrina Dunbar, Investor Relations. Please go ahead.
Thank you, operator, and thank you to everyone for joining us today. On the call, we have Katherine Stueland, President and Chief Executive Officer; Bryan Dechairo, Chief Operations Officer; and Kevin Feeley, Chief Financial Officer. Earlier today, GeneDx released financial results for the third quarter ended September 30, 2025.
Before we begin, please take note of our cautionary statement. We may make forward-looking statements on today's call, including about our business plans, updated 2025 guidance and outlook. Forward-looking statements inherently involve risks and uncertainties and only reflect our view as of today, October 28, and we are under no obligation to update.
When
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
